BRAF and thyroid gland carcinoma: Since BRAF-mutated thyroid cancer highly correlates with the glycolytic metabolic pathway (Nagarajah et al. 2015), suppressing glycolysis may enhance the efficacy of PLX4032 in treating ATC.